Pfizer (PFE) is a Healthcare company in the Drug Manufacturers General industry. It has a market capitalization of $167.52B, a trailing price-to-earnings ratio of 9.6 and a free-cash-flow yield of 5.4%. Over the most recent reported fiscal year, revenue declined 1.6% and free cash flow per share fell 7.9%. Nama's AI scorecard rates it Buy, 6.6 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Buy · 6.6/10
Positive, at the low end of Buy. As of Nov 7, 2026.
Momentum
Rising · +12.7% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-52.4%
How far the last close sits under the highest price of the past five years.
Market cap
$167.52B
Trailing P/E
9.6
Price / book
2.0
Price / sales
2.6
FCF yield
5.4%
Dividend yield
5.8%
Gross margin
73.2%
Operating margin
26.7%
Net margin
6.8%
Revenue growth (YoY)
-1.6%
Revenue growth (3-yr annual)
-14.8%
EPS growth (YoY)
+3.9%
FCF/share growth (YoY)
-7.9%
Beta
0.3
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers General
PFE earnings
Next report: Feb 2, 2027 (Q4 2026, EPS estimate $0.71).
Beat the EPS estimate in 4 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 3, 2026
$0.87
$0.74
+17.6%
$16.58B
Q2 2026
Aug 4, 2026
$0.77
$0.68
+13.2%
$15.03B
Q1 2026
May 5, 2026
$0.75
$0.72
+4.2%
$14.45B
Q4 2025
Feb 3, 2026
$0.66
$0.57
+15.8%
$17.56B
PFE analyst price target
Median target $30.00 from 26 analysts, ranging $25.00 – $36.00.
Nama's AI scorecard currently rates Pfizer Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is PFE's P/E ratio?
Pfizer trades at a trailing price-to-earnings ratio of 9.6.
When does PFE report earnings?
Pfizer's next scheduled report is on Feb 2, 2027. Analysts expect EPS of $0.71.
What is the PFE price target?
The median analyst price target from 26 analysts is $30.00, with a range of $25.00 – $36.00.
Is PFE Shariah compliant?
Nama's AAOIFI-style screen reads Pfizer as Not Shariah Compliant. At least one of the three ratios or the industry test failed.